score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.475	320.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0.0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	320.0	0.45	1.0	NRAS p.Q61K (Missense)	1.0	MEL-IPI_Pat126	MEL-IPI_Pat126-Tumor-SM-5X2R4	MEL-IPI_Pat126-Normal-SM-5VWHO
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.P123L	0.3056	36.0	8e-06	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056													0	134.0	0.4925	1.0	ERCC2 p.P123L (Missense)	0.0	MEL-IPI_Pat126	MEL-IPI_Pat126-Tumor-SM-5X2R4	MEL-IPI_Pat126-Normal-SM-5VWHO
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat126		
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.L33F	0.3702	208.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf													0	153.0	0.3464	1.0	TSC1 p.L33F (Missense)		MEL-IPI_Pat126	MEL-IPI_Pat126-Tumor-SM-5X2R4	MEL-IPI_Pat126-Normal-SM-5VWHO
Investigate Actionability	Preclinical			Copy Number	FGFR1	Deletion				0.0	0.0		Investigate Actionability	Infigratinib	FGFR inhibition	Targeted therapy	A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.	Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33.	https://doi.org/10.1158/2159-8290.CD-12-0210													0				FGFR1 Deletion		MEL-IPI_Pat126	MEL-IPI_Pat126-Tumor-SM-5X2R4	
Biologically Relevant				Somatic Variant	MTOR	Missense	p.P1117L	0.4556	180.0	0.0	0.0																					0	147.0	0.4354	1.0	MTOR p.P1117L (Missense)		MEL-IPI_Pat126	MEL-IPI_Pat126-Tumor-SM-5X2R4	MEL-IPI_Pat126-Normal-SM-5VWHO
Biologically Relevant				Copy Number	TSC2	Amplification				0.0	0.0																					0				TSC2 Amplification		MEL-IPI_Pat126	MEL-IPI_Pat126-Tumor-SM-5X2R4	
Biologically Relevant				Copy Number	CHEK2	Deletion				0.0	0.0																					0				CHEK2 Deletion		MEL-IPI_Pat126	MEL-IPI_Pat126-Tumor-SM-5X2R4	
Biologically Relevant				Copy Number	PALB2	Deletion				0.0	0.0																					0				PALB2 Deletion		MEL-IPI_Pat126	MEL-IPI_Pat126-Tumor-SM-5X2R4	
Biologically Relevant				Copy Number	LIMK2	Deletion				0.0	0.0																					0				LIMK2 Deletion		MEL-IPI_Pat126	MEL-IPI_Pat126-Tumor-SM-5X2R4	
Biologically Relevant				Copy Number	EWSR1	Deletion				0.0	0.0																					0				EWSR1 Deletion		MEL-IPI_Pat126	MEL-IPI_Pat126-Tumor-SM-5X2R4	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		MEL-IPI_Pat126		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.641																									0				COSMIC Signature (version 2) 7 (64%)		MEL-IPI_Pat126		
